Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › TRIUMPH-4 (obesity + knee osteoarthritis)

TRIUMPH-4 (obesity + knee osteoarthritis)

Retatrutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Retatrutide
Population
obesity
Phase
3
Participants
148
Duration
68 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
retatrutide 9 mgobesity68148−26.4 % vs −2.1 %
Δ −24.3 pp
−20.0 % vs −4.6 %
Δ −15.4 pp
—12.9 vs 4.0———9.5 vs 2.0—verified
retatrutide 12 mgobesity68148−28.7 % vs −2.1 %
Δ −26.6 pp
−23.7 % vs −4.6 %
Δ −19.1 pp
—18.2 vs 4.0———10.8 vs 2.0−14.0verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (9)
  • retatrutide 9 mg · weight_eff · Article body, paragraph 4
    while those on 9 mg lost 26.4%
  • retatrutide 9 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Adverse events 19 27 (18.2) 6 (4.0) 52 (11.7) 4 (2.8) 12 (8.4) 22 (15.3) 9 (6.2) 47 (8.2) leading to (12.9)
  • retatrutide 9 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
    -20.0 (0.9) -23.7 (1.0) -4.6
  • retatrutide 9 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Serious adverse 14 (9.5) 16 (10.8) 3 (2.0) 33 (7.4) 6 (4.2) 14 (9.8) 21 (14.6) 10 (6.9) 51 (8.9)
  • retatrutide 12 mg · weight_eff · Article body, paragraph 4
    patients receiving the 12 mg dose losing an average of 28.7% of their body weight
  • retatrutide 12 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Adverse events 19 27 (18.2) 6 (4.0)
  • retatrutide 12 mg · sbp · The Phase 3 TRIUMPH-4 Trial, paragraph 3
    At the highest dose, systolic blood pressure decreased by 14.0 mm Hg.
  • retatrutide 12 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
    -20.0 (0.9) -23.7 (1.0) -4.6
  • retatrutide 12 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
    Serious adverse 14 (9.5) 16 (10.8) 3 (2.0)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: TRIUMPH-4 (obesity + knee osteoarthritis). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/triumph-4/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.